Physician profile
Anne Morse
NPI 1033499207
$581,594.33
in general payments reported to CMS, 2019-2025
10 companies · $162K in 2025
The $162K reported for 2025 was more than what 99% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90K · 2020: $44K · 2021: $43K · 2022: $86K · 2023: $55K · 2024: $101K · 2025: $162K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Consulting Fee: $99K · Honoraria: $74K · Travel and Lodging: $26K · Food and Beverage: $4,798 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,570.25 |
| Consulting Fee | $99,191.25 |
| Honoraria | $74,212.50 |
| Travel and Lodging | $25,523.67 |
| Food and Beverage | $4,797.83 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $301,245.97 | 2019-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $147,272.39 | 2023-2025 | Lumryz |
| Lilly USA, LLC | $49,079.24 | 2025 | Zepbound |
| Alkermes, INC. | $27,759.40 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $27,313.24 | 2023-2025 | |
| Harmony Biosciences LLC | $11,724.70 | 2021-2025 | |
| Eli Lilly and Company | $9,409.89 | 2025 | Zepbound |
| Axsome Therapeutics, INC. | $3,604.50 | 2025 | Sunosi |
| Eisai INC. | $2,160.00 | 2023 | |
| Novartis Pharmaceuticals Corporation | $2,025.00 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anne Morse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.